系统性硬化症循环滤泡辅助性T细胞增多并通过IL-21通路促进浆母细胞分化且可被鲁索替尼抑制
该研究通过流式细胞术分析50例系统性硬化症(SSc)患者和32名健康对照的循环滤泡辅助性T(cTfh)细胞,发现SSc患者cTfh细胞增多且与弥漫型SSc和动脉性肺动脉高压相关。体外共培养实验显示SSc的cTfh细胞通过IL-21通路增强CD19+CD27+CD38hi B细胞分化和IgG/IgM分泌,阻断IL-21R或使用JAK1/2抑制剂鲁索替尼可减少浆母细胞和免疫球蛋白产生。
要点
- SSc患者循环Tfh细胞增多,尤其在弥漫型SSc和合并动脉性肺动脉高压者。
- SSc的cTfh细胞高表达BCL-6和IL-21,增强B细胞分化为浆母细胞。
- 鲁索替尼或阻断IL-21R可抑制Tfh细胞刺激浆母细胞和Ig产生。
核心结论
- 循环Tfh细胞在SSc中增多并与疾病严重程度相关。
- IL-21通路或JAK1/2阻断(鲁索替尼)可能是SSc有前景的治疗策略。
研究设计与样本
- 研究纳入50例SSc患者和32名健康对照,用流式细胞术分析cTfh细胞。
- 体外分选cTfh与B细胞共培养进行功能分析,ELISA检测IgG和IgM。
主要发现
- SSc患者cTfh细胞数量较健康对照增多,且在弥漫型SSc和动脉性肺动脉高压患者中增加更明显。
- SSc的cTfh细胞呈活化表型,BCL-6表达高,产生IL-21的能力较健康对照增强。
- SSc的cTfh细胞通过IL-21通路刺激CD19+CD27+CD38hi B细胞分化和IgG/IgM分泌的能力高于健康对照Tfh细胞。
- 阻断IL-21R或使用JAK1/2抑制剂鲁索替尼可降低Tfh细胞刺激浆母细胞的能力并减少Ig产生。
临床怎么用
- SSc患者循环Tfh细胞增多与弥漫型及肺动脉高压相关,提示其作为疾病活动/严重度标志的潜在价值。
- IL-21通路和JAK1/2(鲁索替尼)是SSc中靶向Tfh-B细胞交互的潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic sclerosis (SSc) is an autoimmune disease characterised by widespread fibrosis, microangiopathy and autoantibodies. Follicular helper T (Tfh) cells CD4+CXCR5+PD-1+ cooperate with B lymphocytes to induce the differentiation of plasmocytes secreting immunoglobulins (Ig). Circulating Tfh (cTfh) cells are increased in several autoimmune diseases. However, there are no data about cTfh cells and their interaction with B cells in SSc. The aim of this study was to perform a quantitative and functional analysis of cTfh cells in SSc. METHODS: Using flow cytometry, we analysed cTfh cells from 50 patients with SSc and 32 healthy controls (HC). In vitro coculture experiments of sorted cTfh and B cells were performed for functional analysis. IgG and IgM production were measured by ELISA. RESULTS: We observed that cTfh cell numbers are increased in patients with SSc compared with HC. Furthermore, the increase in cTfh cells was more potent in patients with severe forms of SSc such as diffuse SSc and in the presence of arterial pulmonary hypertension. cTfh cells from patients with SSc present an activated Tfh phenotype, with high expression of BCL-6, increased capacity to produce IL-21 in comparison with healthy controls. In vitro, cTfh cells from patients with SSc had higher capacity to stimulate the differentiation of CD19+CD27+CD38hi B cells and their secretion of IgG and IgM through the IL-21 pathway than Tfh cells from healthy controls. Blocking IL-21R or using the JAK1/2 inhibitor ruxolitinib reduced the Tfh cells' capacity to stimulate the plasmablasts and decreased the Ig production. CONCLUSIONS: Circulating Tfh cells are increased in SSc and correlate with SSc severity. The IL-21 pathway or JAK1/2 blockade by ruxolitinib could be a promising strategy in the treatment of SSc.
引用
- Ricard L, Jachiet V, Malard F, et al. Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib. Ann Rheum Dis. 2019. PMID: 30760472. doi:10.1136/annrheumdis-2018-214382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。